{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"62.5","value":"114"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"}],"units":"Participants"}],"title":"Cycle 1 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.4","value":"37.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"}],"units":"Participants"}],"title":"Cycle 3 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"46.8","value":"45.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"}],"units":"Participants"}],"title":"Cycle 5 Day 1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"}],"units":"Participants"}],"dispersionType":"Standard Deviation","groups":[{"description":"Participants with stages I to III CTCL were treated with E7777 9 mcg/kg by IV infusion over 60 minutes on 5 consecutive days in 21-day cycles for up to 8 cycles or disease progression or unacceptable toxicity in Lead-in part and in Main study part and were presented together here, as planned.","id":"OG000","title":"Main Study Part: E7777 9 mcg/kg"}],"paramType":"MEAN","populationDescription":"Main study part PK analysis set included all participants from whom at least one quantifiable concentration of E7777 was observed at 9 mcg/kg dose (both Main Study and Lead-In). Here \"overall number of participants analyzed\" signifies participants who were evaluable for this outcome measure. Here \"number analyzed\" signifies participants who were evaluable for this outcome measure at given timepoints.","reportingStatus":"POSTED","timeFrame":"Cycles 1, 3 and 5 Day 1: Pre-dose up to 300 minutes post-dose (Cycle length was 21 days)","title":"Main Study Part: Maximum Serum Concentration (Cmax) of E7777","type":"SECONDARY","unitOfMeasure":"ng/mL"}